D.C. Circuit Rejects Mylan's Bid To Make Generic Duragesic

Law360, New York (December 7, 2004, 12:00 AM EST) -- A U.S. appeals court in Washington, D.C. has rejected Mylan Laboratories' bid to market a generic version of Johnson & Johnson's Duragesic pain-relief skin patch.

The United States Court of Appeals for the District of Columbia Circuit upheld a June decision by the Food and Drug Administration and affirmed another court ruling that allowed Johnson & Johnson to retain exclusive rights to Duragesic until January as a reward for testing the effects of the drug on children.

The D.C. Circuit held that the FDA did not...
To view the full article, register now.